{"DataElement":{"publicId":"7576131","version":"1","preferredName":"Calculated Panel Reactive Antibody Assessment Number","preferredDefinition":"The determination of the calculated panel reactive antibody (CPRA), which is based on the number/type of unacceptable HLA antigens to which an organ recipient has been sensitized, and which algorithmically estimates the level of sensitization in the recipient. The CPRA is computed from HLA antigen frequencies in a given donor population using both anti-HLA class I and class II antibody specificities; it also represents the percentage of actual organ donors that express one or more unacceptable HLA antigens to which a recipient may react adversely.","longName":"CPRA_NUM","context":"DCP","contextVersion":"1","DataElementConcept":{"publicId":"7576130","version":"1","preferredName":"Calculated Panel Reactive Antibody Assessment","preferredDefinition":"The determination of the calculated panel reactive antibody (CPRA), which is based on the number/type of unacceptable HLA antigens to which an organ recipient has been sensitized, and which algorithmically estimates the level of sensitization in the recipient. The CPRA is computed from HLA antigen frequencies in a given donor population using both anti-HLA class I and class II antibody specificities; it also represents the percentage of actual organ donors that express one or more unacceptable HLA antigens to which a recipient may react adversely._The final result of a determination of the value, significance, or extent of.","longName":"7576128v1.0:2465182v1.0","context":"DCP","contextVersion":"1","ObjectClass":{"publicId":"7576128","version":"1","preferredName":"Calculated Panel Reactive Antibody Measurement","preferredDefinition":"The determination of the calculated panel reactive antibody (CPRA), which is based on the number/type of unacceptable HLA antigens to which an organ recipient has been sensitized, and which algorithmically estimates the level of sensitization in the recipient. The CPRA is computed from HLA antigen frequencies in a given donor population using both anti-HLA class I and class II antibody specificities; it also represents the percentage of actual organ donors that express one or more unacceptable HLA antigens to which a recipient may react adversely.","longName":"C132381","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Calculated Panel Reactive Antibody Measurement","conceptCode":"C132381","definition":"The determination of the calculated panel reactive antibody (CPRA), which is based on the number/type of unacceptable HLA antigens to which an organ recipient has been sensitized, and which algorithmically estimates the level of sensitization in the recipient. The CPRA is computed from HLA antigen frequencies in a given donor population using both anti-HLA class I and class II antibody specificities; it also represents the percentage of actual organ donors that express one or more unacceptable HLA antigens to which a recipient may react adversely.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BAD52F93-EE5B-1F3A-E053-4EBD850A8B04","latestVersionIndicator":"Yes","beginDate":"2021-02-08","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2021-02-08","modifiedBy":"ONEDATA","dateModified":"2021-02-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2465182","version":"1","preferredName":"Assessed","preferredDefinition":"Having determined the value, significance, or extent of.","longName":"C25217","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Assessment","conceptCode":"C25217","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F836E72-26FF-3EB2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-03-22","modifiedBy":"ONEDATA","dateModified":"2006-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"DCP:Division of Cancer Prevention","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BAD52F93-EE69-1F3A-E053-4EBD850A8B04","latestVersionIndicator":"Yes","beginDate":"2021-02-08","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2021-02-08","modifiedBy":"ZHANGWE","dateModified":"2021-09-09","changeDescription":"Created for DCP SVAR NWU2015-06-02#SVAR02022021 wz 2/8/2021","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6013152","version":"1","preferredName":"Number","preferredDefinition":"A numeral or string of numerals expressing value, quantity, or identification.","longName":"6013152v1.0","context":"DCP","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","minLength":null,"maxLength":"19","minValue":null,"maxValue":null,"decimalPlace":"4","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2233101","version":"1","preferredName":"Number","preferredDefinition":"Number; a concept of quantity derived from zero and units; a numeral or string of numerals that is used for identification.","longName":"C25337","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Number","conceptCode":"C25337","definition":"A numeral or string of numerals expressing value, quantity, or identification.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F920A342-1134-2A6A-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-09","modifiedBy":"ONEDATA","dateModified":"2005-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"DCP:Division of Cancer Prevention","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"5CC656B6-21FF-60CD-E053-F662850ADF4C","latestVersionIndicator":"Yes","beginDate":"2017-10-30","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-10-30","modifiedBy":"TITARENI","dateModified":"2021-09-15","changeDescription":"11/19/18 jk upd reg status from Application to Qualified; added MCL CSI reference.  10/30/2017 wz created for DCP NWU datatype and size constraint. 09/15/2021 it added the number of decimal places (4)","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Calculated Panel of Reactive","type":"Preferred Question Text","description":"Calculated Panel of Reactive Antibodies (cPRA)","url":null,"context":"DCP"},{"name":"DCP-Text-1","type":"Alternate Question Text","description":"Enter pre-transplant calculated panel of reactive antibodies (required if yes)","url":null,"context":"DCP"}],"origin":"DCP:Division of Cancer Prevention","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BAD43B28-1277-38D5-E053-4EBD850A48F1","latestVersionIndicator":"Yes","beginDate":"2021-02-08","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2021-02-08","modifiedBy":"ZHANGWE","dateModified":"2021-09-09","changeDescription":"Created for DCP SVAR NWU2015-06-02#SVAR02022021 wz 2/8/2021","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}